tiprankstipranks
Trending News
More News >

Thiogenesis Therapeutics Grants Stock Options to Directors

Story Highlights
  • Thiogenesis is a biopharmaceutical company developing sulfur-containing prodrugs.
  • The company granted 400,000 stock options to directors, aligning interests with long-term goals.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Thiogenesis Therapeutics Grants Stock Options to Directors

Don’t Miss TipRanks’ Half-Year Sale

An update from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.

Thiogenesis Therapeutics Corp announced the approval of a grant of 400,000 common share purchase options to two directors, exercisable at $0.77, under the company’s Omnibus Equity Incentive Plan. This strategic move is likely aimed at aligning the interests of the directors with the company’s long-term goals, potentially impacting its operational dynamics and market positioning positively.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. It focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, aiming to treat serious pediatric diseases with unmet medical needs. Their lead product candidate, TTI-0102, is in a Phase 2 clinical trial for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) and plans to initiate trials for Leigh syndrome, Rett syndrome, and pediatric MASH.

Average Trading Volume: 32,749

Technical Sentiment Signal: Buy

Current Market Cap: C$32.41M

See more insights into TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1